The FDA has expanded the approval of an intravenous injection for the treatment of metastatic or unresectable melanoma to include use in pediatric patients.
The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.
